Tag - km-biologics

 
 

KM BIOLOGICS

Japan Times
JAPAN / Science & Health
Mar 23, 2021
Japanese firms launch domestic clinical trials for COVID-19 vaccines
Even as Daiichi Sankyo and KM Biologics begin work to prove their shots' efficacy and safety, the public is unlikely to have access to them until fiscal 2022 at the earliest.
Japan Times
ASIA PACIFIC / FOCUS
Dec 29, 2020
'I won’t take it': China struggles to get the world to trust its vaccines
That uncertainty presents another roadblock in China's efforts to extend its political influence across Asia, Africa and South America.
Japan Times
ASIA PACIFIC / Science & Health
Sep 2, 2020
Vaccine front-runner held back by China’s spat with Canada
One of the world’s fastest-moving efforts to develop a COVID-19 vaccine is falling behind rivals, its advance appearing to be stymied by political tensions between China and Canada and concerns its shot may not work as well as others.
Japan Times
WORLD / Science & Health / FOCUS
Aug 31, 2020
Scientists see downsides to top COVID-19 vaccines from Russia and China
High-profile COVID-19 vaccines developed in Russia and China share a potential shortcoming: They are based on a common cold virus that many people have been exposed to, potentially limiting their effectiveness, some experts say.
Japan Times
ASIA PACIFIC / Science & Health
Jul 12, 2020
China's CanSino in talks for COVID-19 vaccine Phase III trial overseas
Chinese vaccine developer CanSino Biologics is in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine, its co-founder said on Saturday.
Japan Times
ASIA PACIFIC / Science & Health
Jul 2, 2020
How China's CanSino Biologics jumped to the front of the coronavirus vaccine race
The firm has boosted its scientific prowess by tying up with the Canadian government's largest research organization, maintaining links despite geopolitical rows.
Japan Times
BUSINESS / Companies
May 16, 2017
Samsung looks beyond smartphones to next-generation biologics market
The Samsung brand is best known for its smartphones and wide-screen TVs. Yet behind the scenes the conglomerate is also making a name as a contract manufacturer of complex medicines to treat diseases like cancer.

Longform

Later this month, author Shogo Imamura will open Honmaru, a bookstore that allows other businesses to rent its shelves. It's part of a wave of ideas Japanese booksellers are trying to compete with online spaces.
The story isn't over for Japan's bookstores